Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors

ABSTRACT: In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors. Patients will be treated with an ARG1 vaccine every third week for 45 weeks.

DISEASE(S): Ovarian Cancer,Squamous Cell Carcinoma Of Head And Neck,Carcinoma,Squamous Cell Carcinoma Of The Head And Neck,Melanoma,Colorectal Cancer,Non Small Cell Lung Cancer,Urothelial Carcinoma,Breast Cancer,Malignant Melanoma,Metastatic Cancer

PROVIDER: 2285526 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR